Results 61 to 70 of about 745,289 (215)
A Non-Covalent Antibody Complex for the Delivery of anti-cancer drugs [PDF]
, 2019 Antibody drug conjugates (ADCs), which are obtained by coupling a potent cytotoxic agent to a monoclonal antibody (mAb), are traditionally bound in a random way to lysine or cysteine residues, with the final product's heterogeneity having an important ...
Grigoletto, Antonella +5 more
core +1 more source
Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells
Biomedicines, 2018 Targeted cancer therapy includes, amongst others, antibody-based delivery of toxic payloads to selectively eliminate tumor cells. This payload can be either a synthetic small molecule drug composing an antibody-drug conjugate (ADC) or a cytotoxic protein
Sandra Jordaan +6 more
doaj +1 more source
Indian Journal of Medical and Paediatric Oncology, 2020 Antibody drug conjugates (ADCs) are chemically engineered drugs consisting of monoclonal antibody (mAb) and cytotoxic compound attached chemically by a linker. Upon attachment to a specific target antigen, ADC enters into the cell and payload is released,
Stalin Bala, Siva K Prasad
doaj +1 more source
Targeted Cell-to-Cell Delivery of Protein Payloads via the Granzyme-Perforin Pathway
Molecular Therapy: Methods & Clinical Development, 2017 There is great potential for engineering cellular therapeutics by repurposing biological systems. Here, we report utilization of the granzyme-perforin pathway of cytotoxic lymphocytes as a cell-to-cell protein delivery module. We designed and constructed
Daniel J. Woodsworth +3 more
doaj +1 more source
A Vegetable Oil-Based Organogel for use in pH-Mediated Drug Delivery [PDF]
, 2015 Organogels prepared with vegetable oils as the liquid organic phase present an excellent platform for the controlled delivery of hydrophobic guest molecules.
Algy Kazlauciunas +62 more
core +1 more source
Patritumab deruxtecan induces immunogenic cell death
OncoImmunologyAntibody-drug conjugates (ADCs) enable targeted delivery of cytotoxic payload to cancer cells. Here, we characterized the mode of action of the ADC patritumab deruxtecan, which is a monoclonal antibody specific for Erb-B2 Receptor Tyrosine Kinase 3 ...
Sabrina Forveille +9 more
doaj +1 more source
A mechanistic tumor penetration model to guide antibody drug conjugate design. [PDF]
PLoS ONE, 2015 Antibody drug conjugates (ADCs) represent novel anti-cancer modalities engineered to specifically target and kill tumor cells expressing corresponding antigens.
Christina Vasalou +2 more
doaj +1 more source
Cellular delivery of antibodies: effective targeted subcellular imaging and new therapeutic tool [PDF]
, 2010 It is already more than a century since the pioneering work of the Nobel Laureate Ehrlich gave birth to the side chain theory1, which helped to define antibodies and their ability to target specific biological sites.
Andrew L. Lewis +6 more
core +1 more source
Fabrication of viable cyborg cells with cyclodextrin functionality [PDF]
, 2013 We describe two alternative methods for surface functionalisation of Saccharomyces cerevisiae cells with cyclodextrin molecules without affecting the cell viability.
Mathapa, Baghali G., Paunov, Vesselin N.
core +2 more sources
Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs
Frontiers in Cell and Developmental BiologyAntibody-drug conjugates (ADCs), often referred to as “intelligent biological missiles,” have garnered significant attention in the rapidly evolving landscape of cancer therapy. ADCs represent a sophisticated approach by integrating monoclonal antibodies
Dan Wu +9 more
doaj +1 more source